Evidence map›Paper›PMID 39000029›Full record

ArticleInternational journal of molecular sciences2024

The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherapy.

Yu-Ze Luan, Chi-Chih Wang, Chia-Ying Yu, Ya-Chuan Chang, Wen-Wei Sung, Ming-Chang Tsai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu-Ze LuanSchool of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
Chi-Chih WangSchool of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
Chia-Ying YuSchool of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
Ya-Chuan ChangSchool of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.ORCID 0000-0002-3158-8690
Wen-Wei SungSchool of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.ORCID 0000-0002-2375-0029
Ming-Chang TsaiSchool of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.

Funding

Chung Shan Medical University Hospital CSH-2023-D-002National Science and Technology Council NSTC 112-2314-B-040-010-
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge in terms of diagnosis and treatment, with limited therapeutic options and a poor prognosis. This study explored the potential therapeutic role of NPS-1034, a kinase inhibitor targeting MET and AXL, in PDAC. The investigation included monotherapy with NPS-1034 and its combination with the commonly prescribed chemotherapy agents, fluorouracil and oxaliplatin. Our study revealed that NPS-1034 induces cell death and reduces the viability and clonogenicity of PDAC cells in a dose-dependent manner. Furthermore, NPS-1034 inhibits the migration of PDAC cells by suppressing MET/PI3K/AKT axis-induced epithelial-to-mesenchymal transition (EMT). The combination of NPS-1034 with fluorouracil or oxaliplatin demonstrated a synergistic effect, significantly reducing cell viability and inducing tumor cell apoptosis compared to monotherapies. Mechanistic insights provided by next-generation sequencing indicated that NPS-1034 modulates immune responses by inducing type I interferon and tumor necrosis factor production in PDAC cells. This suggests a broader role for NPS-1034 beyond MET and AXL inhibition, positioning it as a potential immunity modulator. Overall, these findings highlight the anticancer potential of NPS-1034 in PDAC treatment in vitro, both as a monotherapy and in combination with traditional chemotherapy, offering a promising avenue for further in vivo investigation before clinical exploration.

Indexed as

ApoptosisCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAxl Receptor Tyrosine KinaseCell Line, TumorCell MovementCell ProliferationCell SurvivalEpithelial-Mesenchymal TransitionFluorouracilHumansOxaliplatinProtein Kinase InhibitorsProto-Oncogene Proteins c-metAntineoplastic AgentsAxl Receptor Tyrosine KinaseFluorouracilMET protein, humanOxaliplatinProtein Kinase InhibitorsProto-Oncogene Proteins c-metReceptor Protein-Tyrosine KinasesfluorouracilNPS-1034oxaliplatinpancreatic cancersynergistic effect

Identifiers

PMID39000029
PMCPMC11241054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.